Key result
A recurring YYDRxG motif in the CDR H3 region of human antibodies facilitates targeting of a highly conserved epitope on the SARS-CoV-2 receptor binding domain, enabling broad neutralization.
Why the study?
Studying the antibody response to SARS-CoV-2 informs how the human immune system responds to antigenic variants and other SARS-related viruses.
The identification of a recurrent YYDRxG motif in anti-SARS-CoV-2 antibodies reveals a conserved epitope targeting strategy that can aid in the design of pan-sarbecovirus vaccines and therapeutics.
May advance pan-sarbecovirus vaccine design; leaves open human translation from animal data.
Studying the antibody response to SARS-CoV-2 informs on how the human immune system can respond to antigenic variants as well as other SARS-related viruses. Here, we structurally and functionally characterized a potent human antibody ADI-62113 that also neutralizes SARS-CoV- 2 variants of concern and cross-reacts with many other sarbecoviruses. A YYDRxG motif encoded by IGHD3-22 in CDR H3 facilitates targeting to a highly conserved epitope on the SARS-CoV-2 receptor binding domain. A computational search for a YYDRxG pattern in publicly available sequences identified many antibodies with broad neutralization activity against SARS-CoV-2 variants and SARS-CoV. Thus, the YYDRxG motif represents a common convergent solution for the human humoral immune system to counteract sarbecoviruses. These findings also suggest an epitope targeting strategy to identify potent and broadly neutralizing antibodies that can aid in the design of pan-sarbecovirus vaccines and antibody therapeutics. Short Summary Decryption of a recurrent sequence feature in anti-SARS-CoV-2 antibodies identifies how potent pan-sarbecovirus antibodies target a conserved epitope on the receptor binding domain.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied SARS-CoV-2. YYDRxG motif antibodies was evaluated. A recurring YYDRxG motif in the CDR H3 region of human antibodies facilitates targeting of a highly conserved epitope on the SARS-CoV-2 receptor binding domain, enabling broad neutralization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: